Document
RDF description of Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study - http://irises.uniss.it/resource/item/355306
Academic Article
Generically Dependent Continuant
Article
Information Content Entity
Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study